Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial

Fig. 1

Flow chart. * The subjects (one in the Eutropin group and two in the comparator group) required the use of a prohibited medication for the treatment of adverse events, and hence, they were withdrawn from the study at the discretion of the investigator because of expected protocol deviation (use of prohibited medications)

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172